FCMV
EWTX icon

Foresite Capital Management VI’s Edgewise Therapeutics EWTX Stock Holding History

Foresite Capital Management VI’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-585,000
Closed -$7.67M – 15
2025
Q2 		$7.67M Hold
585,000
– – 4.31% 7
2025
Q1 		$12.9M Hold
585,000
– – 7.05% 6
2024
Q4 		$15.6M Buy
+585,000
New +$18.6M 6.96% 6

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Foresite Capital Management VI's EWTX Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 585,000 shares — an estimated $7.67M sold.

Foresite Capital Management VI first reported a position in EWTX in Q4 2024 and held it in 3 quarters. The position peaked at $15.6M in Q4 2024. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 585,000 Edgewise Therapeutics shares in Q3 2025, an estimated $7.67M.
  • Foresite Capital Management VI first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 3 quarters.
  • Foresite Capital Management VI's Edgewise Therapeutics position peaked at $15.6M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.